Novo Nordisk cut its full-year guidance as U.S. sales continue to be hurt by copycat versions of its blockbuster Wegovy ...

Novo Nordisk (NVO) stock falls as the company names a new CEO and cuts outlook citing pressure on obesity drug sales. Eli ...

Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective ...

Shares of Novo Nordisk A/S (NYSE:NVO), the Danish pharmaceutical giant renowned for its weight-loss drug Wegovy and diabetes treatment Ozempic, experienced a significant downturn on Tuesday following ...

Professor Lene Oddershede Chief Scientific Officer, Planetary Science & Technology at the Novo Nordisk Foundation talks about the applications of quantum computing at the tech disruptors podcast. She ...

Novo Nordisk appoints Maziar Mike Doustdar as the new CEO to tackle falling sales and shares amid stiff competition in the ...

Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for the first six months of ...

Danish pharmaceutical giant Novo Nordisk on Tuesday cut its full-year sales and profit guidance, citing weaker growth expectations for its Wegovy obesity drug in the key U.S. market. Shares were down ...

The drugmaker unexpectedly cuts its full-year guidance, citing lower sales expectations for its blockbuster drugs Wegovy and ...

Novo Nordisk has lowered its sales and profit forecasts for the second time this year due to competitive pressures in the ...

Novo Nordisk’s shares plunged by 23 per cent after the pharmaceutical company slashed its sales and profit forecasts for the year amid fierce US competition for its blockbuster weight-loss drugs.